Tjokrowidjaja A, Kok P-S, Antill YC, Scott CL, Mileshkin LR, Friedlander ML, Lee CK. Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas—a meta-analysis. JNCI Cancer Spectrum. 2024;8(6):10.1093/jncics/pkae101
Haggstrom L, Lee YC, Scott C, Harter P, Woelber L, Ledermann J, Gourley C, McNeish IA, Amant F, Ray-Coquard I, Leary A, Oza AM, Tinker A, González Martin A, Cecere SC, Pignata S, Colombo N, Yoshida H, Marth C, Rosengarten O, Moore KN, Gómez-García EM, Tan D, Friedlander ML. How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.International Journal of Gynecological Cancer. 2024;:10.1136/ijgc-2024-005976
Scott CL, Friedlander ML, Francis K, Kartikasari AER, Diamante K, Bound N, Davies C, O’Connell R, Lee YC, Lombard J, Baron-Hay SE, Antill Y, Shannon C, Selva-Nayagam S, Beale PJ, Shield-Artin K, Wakefield M, Vandenberg C, Plebanski M, Lee CK. 747P SOLACE2: A phase II randomized trial of olaparib (O) and durvalumab (D) with or without low dose cyclophosphamide (LDCy) in platinum-sensitive recurrent ovarian cancer (PSROC). Annals of Oncology. 2024;35:10.1016/j.annonc.2024.08.808
Haggstrom LR, Lee YC, Scott CL, Ledermann JA, Gourley C, McNeish I, Amant F, Ray-Coquard IL, Leary A, Oza AM, Tinker A, González-Martín A, Cecere SC, Colombo N, Yoshida H, Marth C, Garcia EMG, Tan DS, Moore KN, Friedlander ML. 764P How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in platinum sensitive recurrent ovarian cancer and long-term outcomes. Annals of Oncology. 2024;35:10.1016/j.annonc.2024.08.825
Nesic K, Krais JJ, Wang Y, Vandenberg CJ, Patel P, Cai KQ, Kwan T, Lieschke E, Ho G-Y, Barker HE, Bedo J, Casadei S, Farrell A, Radke M, Shield-Artin K, Penington JS, Geissler F, Kyran E, Betsch R, Xu L, Zhang F, Dobrovic A, Olesen I, Kristeleit R, Oza A, McNeish I, Ratnayake G, Traficante N, DeFazio A, Bowtell DDL, Harding TC, Lin K, Swisher EM, Kondrashova O, Scott CL, Johnson N, Wakefield MJ. BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance. Molecular Cancer. 2024;23(1):10.1186/s12943-024-02048-1
Rajadevan N, Flinkier A, Saunders H, Lee YC, Scott C, Khaw P, Allan P, Davies C, Andrews J, Wilson M, Lombard JM, Harrison M, Nesfield H, DeFazio A, Meniawy T, Gorringe KL. Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2024;64(4):10.1111/ajo.13792
Smith K, O’Haire S, Markman B, Gan HK, O’Byrne K, Millward M, Tran B, Solomon BJ, Scott C, Kee D, McArthur G, Fellowes A, Khoung-Quang DAK, Ekert P, James P, Xu H, Martyn M, Lynch E, Weerasuriya R, Gaff C, Fox SB, Desai J. Patient Experience of Complex Genomic Sequencing Exploring Patient Preference, Barriers, and Enablers for Delivery. JCO Precision Oncology. 2024;8(8):10.1200/po.23.00247
Xu H, Gitto SB, Ho G-Y, Medvedev S, Shield-Artin K, Kim H, Beard S, Kinose Y, Wang X, Barker HE, Ratnayake G, Hwang W-T, Study AOC, Hansen RJ, Strouse B, Milutinovic S, Hassig C, Wakefield MJ, Vandenberg CJ, Scott CL, Simpkins F. CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience. 2024;27(7):10.1016/j.isci.2024.109978
Xu L, Liddell B, Nesic K, Geissler F, Ashwood LM, Wakefield MJ, Scott CL, Waddell N, Kondrashova O. High-level tumour methylation of BRCA1 and RAD51C is required for homologous recombination deficiency in solid cancers. NAR Cancer. 2024;6(3):10.1093/narcan/zcae033
Manoharan S, Bressel M, James P, Ko Y-A, Hamilton AL, Scott CL, Mileshkin LR, Grossi M, Burdett N, Ananda S, Desai J, Rischin D, Neeson PJ, Bowtell D, Au-Yeung G. Beacon: A phase II study of bevacizumab, atezolizumab, and cobimetinib in patients with recurrent, platinum resistant, high grade serous ovarian cancer.Journal of Clinical Oncology. 2024;42(16_suppl):10.1200/jco.2024.42.16_suppl.5565
